SCHEMBL25764360

SCHEMBL25764360

COC(=O)/C(=C/c1ccc(Br)cc1OC)N=[N+]=[N-]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 13/20 0.40
▸ KDM4E B2RXH2 8/20 0.40
▸ KMT2A Q03164 6/20 0.40
▸ MEN1 O00255 5/20 0.40
▸ SMN1; SMN2 Q16637 5/20 0.37
▸ LMNA P02545 3/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ NPC1 O15118 3/20 0.36
▸ RAB9A P51151 3/20 0.36
▸ GAA P10253 1/20 0.36
▸ MITF O75030 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ KLF5 Q13887 1/20 0.36
▸ HPGD P15428 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ BLM P54132 1/20 0.36
▸ MCL1 Q07820 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30310566 1.00 MAPT (0.40) MAPTKDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL24113174 0.90 MAPT (0.46) MAPTKDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL30310528 0.90 MAPT (0.46) MAPTKDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL29015402 0.90 MAPT (0.46) MAPTKDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL29062696 0.89 MAPT (0.38) MAPTKDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL27891901 0.86 MAPT (0.48) MAPTKDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL30009048 0.85 MAPT (0.38) MAPTKDM4EKMT2AMEN1LMNA
SCHEMBL24113246 0.85 CTSL (0.38) MAPTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL30310695 0.85 CTSL (0.38) MAPTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL24113456 0.85 MAPT (0.38) MAPTKDM4EKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116685576-A Cysteine protease inhibitors and methods of use thereof 美商帕迪斯生物科学公司 2023-09-01 — — CN disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV MAPT 2314/4885KDM4E 3122/4885KMT2A 3383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback